A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial


Por: Climent M, Font A, Duran I, Puente J, Mendez-Vidal M, Saez M, Lobera C, Arija J, Gonzalez-Del-Alba A, Sanchez-Hernandez A, Fita M, Esteban E, Alonso-Gordoa T, Gonzalez B, Maroto P, Lazaro-Quintela M, Cassinello-Espinosa J, Perez-Valderrama B, Garcias C, Castellano D

Publicada: 1 nov 2022 Ahead of Print: 1 sep 2022
Resumen:

ISSN: 09598049





European Journal Of Cancer
Editorial
ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 175 Número:
Páginas: 110-119
WOS Id: 000874933000010
ID de PubMed: 36099670

MÉTRICAS